-
Company Profile
NewPieris Pharmaceuticals Inc – Company Profile
Pieris Pharmaceuticals Inc (Pieris) is a clinical-stage biotechnology company that carries out the discovery and development of anticalin-based drugs. The company’s pipeline product includes inhaled IL-4Rα antagonist Anticalin protein. It offers drug candidates such as PRS-440, PRS-342 and PRS-352, PRS-060/AZD1402, PRS-220, among others. Pieris also carries out AstraZenca programs and Genetech programs against respiratory diseases. The company offers therapeutics for the treatment of respiratory diseases, oncology and other diseases. It leverages Anticalin technology platform to develop and advance its pipeline...
Add to Basket -
Sector Analysis
Gene Therapy Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Oncology Therapy Type (Oncolytic Virotherapy, Gene Transfer, Gene Induced Immunotherapy) and End-user (Hospitals, Diagnostic Centers, Research Institutes), 2022–2027
The gene therapy in oncology market size was valued at US$ 2,045 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 23.7% during 2022-2027. The key to the growth has been the high prevalence of cancer and growing demand for gene therapy over conventional therapies. Additionally, key strategic partnerships and mergers and acquisitions are expected to accelerate market growth. Over the forecast period, the market will witness an  increase in government support for...
-
Sector Analysis
Endometrial Cancer – Global Drug Forecast and Market Analysis to 2030
EC is a uterine malignancy which is often diagnosed in the early stages of the disease due to the common symptom of post-menopausal bleeding. Due to the early diagnosis rate, surgery is the upfront treatment option for patients and only patients with high-risk of relapse are considered for adjuvant therapy with chemotherapy or hormone therapy. The unmet needs associated with EC arise for patients that relapse the upfront therapy since there is a lack of treatments available for advanced and...
-
Sector Analysis
Gene Therapy in Oncology
Unlike conventional treatments such as chemotherapy, gene therapy combines reduced treatment duration (one time treatment in some cases) with higher chances of cure in oncology. This novel therapeutic approach requires direct delivery of genetic material to the patient or in vitro genetic modification of patient cells and subsequent delivery to the patient, which is an uncharted territory in oncology and will necessitate the implementation of new regulatory guidelines and restructuring of the existing treatment algorithms in various oncology indications. In...
-
Sector Analysis
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer – Global Drug Forecast and Market Analysis to 2025
Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+), and triple negative breast cancer (TNBC). The prognoses of HER2-/HR+ and TNBC differ dramatically, as patients with TNBC progress more rapidly towards metastatic disease and only respond to chemotherapy agents. A large number of pipeline agents are being developed in HER2-/HR+ and/or TNBC,...
-
Sector Analysis
Multiple Sclerosis – Competitive Landscape to 2026
Multiple Sclerosis (MS) is primarily considered an inflammatory demyelinating disorder of the CNS due to a dysfunctional immune system, leading to neurological disability1. The etiology of MS remains unknown; however, it is widely regarded as a complex interaction of genetic susceptibility, dysfunction of the immune system, and environmental factors. This report provides an assessment of the pipeline, clinical, and commercial landscape of MS. Overall, GlobalData expects that new drug approvals will expand the treatment options and drive MS market growth...
-
Track & Monitor
Gene Therapy Market Opportunity For CMOs – 2019 PharmSource Edition
This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity.